PCN117 Health Resource Utilisation (HRU) Associated with Skeletal-Related Events (SREs) in Patients with Bone Metastases (BMS): Results From a Retrospective, Multinational European Study  by Gunther, O. et al.
PCN113
COST-UTILITY ANALYSIS OF COMBINATION THERAPY OF PEGYLATED
LIPOSOMAL DOXORUBICIN(PLD) AND CARBOPLATIN FOR KOREAN WOMEN
WITH PLATINUM-SENSITIVE OVARIAN CANCER
Lee HY1, Hong JM1, Yang BM1, Lee TJ1, Kim BG2, Kang SB3, Kim YT4, Kim YM5, Kim JW1,
Yang JM1, Jung YJ1
1Seoul National University, Seoul, South Korea, 2Samsung Medical Center, Seoul, South Korea,
3National Cancer Center, Gyeonggi-Do , South Korea, 4Yon-Sei Severance Hospital, Seoul , South
Korea, 5Asan Medical Center, Seoul, South Korea
OBJECTIVES: Our objective was to perform the cost-utility analysis of comparing
the combination therapy of Pegylated Liposomal Doxorubicin(PLD)/ Carboplatin
with that of Paclitaxel/Carboplatin as a second-line treatment for women with
Platinum-sensitive ovarian cancer among the Koreans.METHODS:Model : Markov
model was constructed with 10-year time horizon. Treatment sequence was con-
sisted of 1st 6th line chemotherapy and best supportive care before death. Cycle
length, time interval for efficacy evaluation of chemotherapy, was 9 weeks. Struc-
ture: The model consists of four health states: Responsive, Progressive, Clinical
Remission and Death. At any given time, a patient may either remain at the current
therapy line or make a transition to the next therapy or death. Effectiveness data:
Median time to progression and survival were obtained through a systematic liter-
ature review and were pooled using meta-analytical approach. In case the required
data was not available, it was elicited from opinions of expert panel. These out-
comes were then converted into transition probabilities using formula. Costs and
utilities: Direct cost included drug acquisition costs, costs for test, monitoring, BSC,
and out-of-pocket cost. Indirect costs included transportation-related expenses.
Utilities were obtained from existing literature. RESULTS: PLD/Carboplatin combi-
nation as the 2nd line therapy in the sequence of treatment turned out to be more
effective but with higher costs, showing ICER of Korean Won(KRW) 19,712,349
(equivalent to US$ 18,093). This result was robust in all the deterministic sensitivity
analyses, only except when the median TTPs were varied. The probability of cost-
effectiveness for PLD/Carboplatin combination therapy was 50.6% at the willing-
ness to pay of KRW 22,000,000 (about US$20,202), which is 2010 Korean GDP per
capita. CONCLUSIONS: It could be safe to assert that the PLD/Carboplatin combi-
nation therapy is an economically valuable option as the 2nd-line chemotherapy
for the treatment of Platinum-sensitive ovarian cancer within the Korean context.
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OBJECTIVES: The combination of doxorubicin and Cyclophosphamide (AC) has
been a standard adjuvant breast-cancer regimen. The purpose of this analysis was
to estimate the cost-effectiveness of AC compared with AT (Doxorubicin and Do-
cetaxel), CMF (Cyclophosphamide, Methotrexate and 5-Fluoruracil) and FEC (5-
Fluoruracil, Epirubicin and Cyclophosphamide) administered as adjuvant therapy
to women with node-positive early breast-cancer in Spain. METHODS: We devel-
oped a multi-country Cost-Utility-Model to simulate the long-term consequences
from initiation of adjuvant-chemotherpy over 10-years. Markov-modelling tech-
nique were used to estimate incidence of complications during chemotherapy (fe-
bril-neutropenia, chemotherapy-induced nausea and vomiting, dose-reduction,
dose-delay, other grade 3 or 4 adverse-events) and long-term consequences like
local or distant-relapse, acute-myelogenous-leukemia, chronic-heart-failure and
death. Monte-Carlo-simulation accounted for uncertainty. The model includes
twelve health-states. Probabilities were derived from clinical and epidemiological
studies; direct costs (2010 Euro) from published sources from the payer’s perspec-
tive. QALYs, life-years and costs were discounted at 5% p.a. RESULTS: Over a 10-
year timeframe, costs associated with AC amounts to 13,265.88€ and 5.85 QALYs
(6.49 LYs). Costs associated with AT are 15,361.89€. The cost-saving potential asso-
ciated to AC amounts to 2,096.01€ per patient with comparable outcomes to AT.
Costs associated with CMF are 14,144.63€ and QALYs and LYs do not differ from AC.
AC dominates both AT and CMF. FEC associated total-costs are 15,138.23€ and 6.02
QALYs (6.81 LYs). Incremental costs vs. AC amounts to 1,872.35€ favorable for AC,
the QALY gains are 0.17 QALYs (0.32 LYs). The incremental cost-effectiveness-ratio
amounts 46,208.13€. Probabilistic sensitivity-analysis demonstrated the robust-
ness of the model regarding input-data and assumptions. From a cost-minimiza-
tion viewpoint AC remains the dominant strategy up to a price of 0.13€/mg (current
price 0.01€/mg). CONCLUSIONS:AC chemotherapy is a cost-effective alternative to
AT, CMF and FEC. AC is characterized by a clear cost advantage and comparable
quality-of-life and life-years.
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OBJECTIVES: Estimate the cost of SREs in patients with bone metastases secondary
to solid tumours (i.e. breast, lung and prostate). METHODS: This study assessed
county-specific HRU (in Germany, Italy, Spain and the UK [EU4]) as attributed by
study investigators to SREs (defined as pathologic fracture [non-vertebral fracture,
NVF; vertebral fracture, VF], radiation to bone [RB], spinal cord compression [SCC]
and surgery to bone [SB]). Cost-conversion was based on country-specific HRU data
(inpatient stays, outpatient visits, emergency room visits, nursing home/long-term
care facility stays, home health visits and outpatient procedures) collected retro-
spectively for 90 days prior to enrolment and prospectively for up to 18-21 months.
Unit costs were collected from 2010 national sources. GBP were converted into
Euros (£11.12867 Euro). RESULTS: A total of 478 eligible patients contributed 893
SREs (109 NVF, 48 VF, 585 RB, 61 SCC and 90 SB) during the study period which, were
used for cost conversions. Mean cost per NVF across the EU4 ranged from 1720€
(Germany) to 3209€ (Spain). Mean cost per VF was lowest in the UK (1015€), was
more than twice as costly in Germany and Italy (2100€) and highest in Spain (6968€).
In the UK, mean cost per RB was about 3 times lower and cost per SCC was approx-
imately twice as costly relative to the other European countries. Mean SB cost was
3348€ in Italy and 4263€ in Spain and was twice as costly in Germany and the UK.
Cost variation was linked to the type of HRU and differences in local unit costs.
CONCLUSIONS:All SREs are associated with substantial costs and cost per SRE type
varied depending on the type of HRU and local unit costs. Preventing SREs in pa-
tients with bone metastases may help to reduce the financial burden to the Euro-
pean healthcare systems.
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OBJECTIVES: The objective of this study was to perform a model-based economic
evaluation of denosumab vs. ZA in the prevention of SREs in patients with bone
metastases from advanced solid tumors based on data from head to head phase III
clinical trials in breast cancer (BrCa), prostate cancer (PrCa) and other solid tumors
(OST), excluding multiple myeloma.METHODS:Three separate three-state Markov
models (On Treatment, Off Treatment, and Dead) were developed for each cancer
type. Constant SRE incidence rates estimated from the clinical trials were used for
denosumab and ZA within each study. Overall survival was not significantly dif-
ferent between treatments, and was estimated using parametric distributions for
extrapolation beyond the trial duration. Analyses were based on a lifetime model
horizon and trial-based discontinuation. SRE-related utility decrements were de-
rived from trial-based EQ-5D data. SRE-related costs and administration cost were
based on local data. Costs were discounted 4% and QALY outcomes at 1.5% accord-
ing to local guidelines. The models predictions were validated by comparing the
SRE predictions against those observed in the clinical trials. RESULTS: Denosumab
resulted in fewer SREs, higher QALYs, lower SRE-related costs, lower administra-
tion cost and higher medication and total cost. The predicted incremental cost-
effectiveness ratio (ICER) per SRE avoided was €1,644, €3,475, and €690 and the ICER
per QALY gained was €26,524, €44,622, and €11,660 for BrCa, PrCa and OST, respec-
tively. One-way sensitivity analyses were performed including administration
cost, SRE and adverse event cost and SRE QALY decrements. Administration costs
were important drivers of results. CONCLUSIONS: Denosumab provides superior
effectiveness vs. ZA with fewer SREs predicted over patients lifetime. The esti-
mated incremental cost/QALY indicates that denosumab is cost-effective vsersus
ZA in The Netherlands and represents good value for money in prevention of SREs
in patients with bone metastases from all advanced solid tumors based on com-
monly accepted thresholds.
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OBJECTIVES: Patients with BMs from advanced cancer experience SREs (radiation/
surgery to bone, pathologic fracture or spinal cord compression). Limited data exist
on the financial burden of SREs. HRU data will support healthcare resource plan-
ning and the assessment of new products that prevent/delay these events.
METHODS: Eligible patients with BMs from breast/lung/prostate cancer or multiple
myeloma were enrolled in centres in Austria, Czech Republic, Finland, Greece,
Poland, Portugal, Sweden and Switzerland. HRU extracted from patient charts in-
cluded inpatient stays, outpatient visits, day care visits, emergency room visits,
procedures, etc. We present HRU data for Austria, Czech Republic, Poland, Sweden
and Switzerland (collected retrospectively from both 3.5 months prior to the SRE
and 3 months after the SRE). RESULTS: A total of 658 eligible patients with at least
one SRE were enrolled across five countries (36%, 13%, 27% and 25% had breast,
lung and prostate cancer and multiple myeloma, respectively). Across all tumour
and SRE types, mean increase from baseline in number of inpatient stays per SRE
for Austria, Czech Republic, Poland, Sweden and Switzerland, respectively, were
1.0(95%CI:0.7-1.3), 0.8(95%CI:0.6-1.0), 0.9(95%CI:0.7-1.1), 0.8(95%CI:0.6-0.9) and
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0.9(95%CI:0.7-1.1), with a mean increase in total length of stays per SRE of
16.4(95%CI:13.1-19.8), 11.4(95%CI:8.0-14.8), 10.9(95%CI:8.8-13.0), 13.4(95%CI:9.3-
17.4) and 17.2(95%CI:13.6-20.7) days, respectively. For the same countries, the mean
increase in number of outpatient visits per SRE were 3.8(95%CI:2.7-4.9), 4.7(95%CI:
3.5-6.0), 1.1(95%CI:0.7-1.5), 1.3(95%CI:0.7-1.8) and 5.2(95%CI:4.0-6.5). Mean increase
in number of procedures per SRE were 10.9(95%CI:9.5-12.2), 6.9(95%CI:5.6-8.2),
4.4(95%CI:3.7-5.0), 4.7(95%CI:3.9-5.6) and 10.1(95%CI:8.8-11.4). Data by SRE type
show considerable HRU variation. CONCLUSIONS: Data indicate that SREs may
result in a mean increase of 0.8–1.0 inpatient stays with a mean total duration of
10.9–17.2 days. SREs are also linked to numerous outpatient visits and procedures.
Thus, a further reduction in the number of SREs by new bone-targeted agents
should reduce the financial burden on European health care systems.
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OBJECTIVES: The main objective of this study was to evaluate the utilisation of
antineoplastic agents in Slovak Republic during the period of 2006-2010.
METHODS: Statistical analysed data including the number of medicine packages,
DDD and financial expenditures were abstracted from the Slovak Institute of Drug
Control. Key data were provided by wholesalers due to their legal obligation to-
wards the SIDC. RESULTS: Consumption of antineoplastic agents in terms of DID
(DDD/1000 inhabitants/day) reached its highest peak in 2007 with 31,12 and the
lowest value of DID was observed in 2009 with 27,30. The total expenditures dou-
bled their volume within period of 2006-2010 from 56,021,412 € to 111,646,240 €
respectively. Number of delivered packages showed slight increase from 426,412 in
2009 to 629,782 in 2010 while price per single package was rising from 131,29 € (2006)
to 197,68 € (2008) and then decreased to 177,28 € (2010). Resulting from further study
the highest consumption in terms of DID was reached by gemcitabine (7,38 in 2006
and 7,21 in 2010), ifosfamide (5,91 in 2006 and 6,94 in 2010) and fourouracil (2,56 in
2006 and 3,26 in 2010). Expressed in financial units the most costly antineoplastic
agent in 2006 was imatinibum with 8 569 021 €, followed by rituximab with
4,896,000 € and irinotecan with 4,888,660 €. In 2010 reached paramount financial
consumption bevacizumab with 17,771,426 €, trastuzumab with 10,173,699 € and
imatinibum with 8,212,353 €. CONCLUSIONS: Expenditures for antineoplastic
agents are continually rising as a result of biological treatment establishment.
There is observed significant increase of their consuption due rheumatic diseases
treatment.
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OBJECTIVES: To review and analyse studies capturing indirect costs of treatment
in EBC. Indirect costs can form a substantial part of the treatment cost and have a
considerable impact on both the patient and society. METHODS: A literature re-
view was conducted to identify publications that included indirect costs of EBC
treatment. Indirect costs were defined as various out-of-pocket expenses or pro-
ductivity losses. Medline, Embase, EmCare, Cochrane, NHSEED, HEED and EconLit
databases were searched for published articles (January 2000 to November 2010),
using pre-specified terms. A targeted internet search also captured publications
from national websites in 10 countries. Indirect cost data were analysed to identify
trends and a gap analysis was performed. RESULTS: Only 28 studies reported rel-
evant data; they included data from economic models (based on thousands of
patients), observational studies (including 22-324 patients), databases and surveys.
The majority of studies reported indirect costs per patient; two studies reported
cost to society, but rarely as part of total costs of EBC. Data collation and reporting
was inconsistent across studies due to a variety of methods, definitions and out-
comes, which made cross-comparisons difficult. Productivity losses and out-of-
pocket costs were the most frequently reported outcomes (54% and 46% of studies,
respectively). Mortality-associated costs were captured in 11% of studies.
CONCLUSIONS: It was difficult to draw quantitative conclusions from the studies
included in this review due to the paucity of studies, lack of standardisation and
inconsistency in reporting of data. Reducing indirect costs would ease the financial
burden to society, owing to the majority of patients being of working age. Identified
cost data will be presented in the forthcoming poster; however, further work is
required.
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OBJECTIVES: To describe the current pattern of care and resource utilisation in
Europe for patients with fludarabine-refractory chronic lymphocytic leukaemia
(CLL) who are either refractory to alemtuzumab (DR) or ineligible for alemtuzumab
due to bulky lymphadenopathy (BFR) METHODS: Medical charts were reviewed
from nine sites in France, Germany, Italy, Spain and the UK. Patient charts with an
index diagnosis of DR or BFR between January 2002 and June 2008 were abstracted,
with a pre and post-index review period of 6 and 18 months respectively. RESULTS:
Data are from an interim analysis of 37 patients, 62% (n23) DR and 38% (n14)
BFR. Median time between first diagnosis and index refractory diagnosis was 5.2
years. Average age was 62.2 (range 41-77), 76% were male and average number of
co-morbidities was 2.2. Many patients (59%) died during the post index period with
median survival following diagnosis of refractory disease being 6.2 months. In the
pre-index period the average number of pharmacotherapy regimens was 0.9 (range
0-3) and in the post-index period 1.4 (range 1-4). During the 24 month review period
the most frequent single agent regimens were alemtuzumab (38% patients) and
methylprednisolone (19%). Patients receiving combination therapy most fre-
quently received rituximab (43%), mainly in combination with CHOP (16%), fludara-
bine/cyclophosphamide (11%), and bendamustine (8%). 89% of patients experi-
enced at least one treatment related adverse event, including infection (76%),
anaemia (76%), thrombocytopenia (68%) and neutropenia (62%). Average number of
post-index A&E visits was 0.8 and inpatient stays 1.9, the majority (86%) relating to
CLL or its treatment. Average inpatient stay was 11.2 days. Most patients (81%) had
multiple diagnostic investigations (average 11.5), predominantly CT scans (average
6.1) and X-rays (average 2.0). CONCLUSIONS: This study demonstrates the high
economic burden and continuing unmet clinical needs of patients with fludara-
bine-refractory CLL disease in Europe.
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OBJECTIVES: Health technology assessment (HTA) is rapidly developing in CEE
countries as new technologies are difficult to finance with scare resources. Re-
searchers often struggle with limited local epidemiologic and cost data. Therefore
transferability of resource utilization from one to other markets is becoming an
interesting topic. Late 2009 we conducted a study of advanced breast cancer in four
CEE markets (Poland, Hungary, Slovak and Czech Republics). The project aimed to
assess treatment sequence and resource used. METHODS: A common question-
naire was distributed to oncologists managing about 30 % of all oncology patients.
The assessed periods of advanced breast cancer were: a) treatment initiation; b)
routine follow-up on active treatment; c) pre-progression follow-up; and d) pro-
gression period. Data were extracted from hospital information systems and pa-
tient=s charts retrospectively. Final results covered individual treatment/disease
periods and total treatment course. RESULTS: Similar proportions of breast cancer
patients precede to second-line treatment, we found differences in patients pro-
ceeding to third line treatment. In Czech about 67 % of treated completed 3 lines
chemotherapy, in Poland it was about 30 %. In Czech and Slovakia taxane mono-
therapy represented the preferred first-line choice, Poland and Hungary favoured
combination chemotherapy. We found differences across countries such as cancer
care organization, guideline availability, number of oncologists. The above men-
tioned differences resulted in cost variations per patient from about 6 thousand
USD (excluding chemotherapy) in Poland to 12 thousand USD in Hungary. Positions
with highest relevance to cost differences were frequency and reimbursement of
in-patient management and BS/palliative care. CONCLUSIONS: As cancer care or-
ganization, treatment algorithms and reimbursement for services differ, there is
limited value in transferring cost data across CEE countries. The observed differ-
ences are especially relevant for cancer care where market access for new technol-
ogies might be un-equal in particular health care systems.
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OBJECTIVES: This research study aimed to investigate the cancer patients’ beliefs
towards disclosing T&CM use to the health care provider. METHODS: Qualitative
methodology was adapted to collect in-depth information with consented cancer
patients. The participants were recruited from the oncology wards at Penang Gen-
eral Hospital from February till July 2010. Patients with different types of cancer and
stages were recruited from the three major ethnic groups in Malaysia namely Ma-
lay, Chinese and Indians. Upon institutional ethical approval and informed con-
sent from the participants, 20 semi-structured interviews were conducted. All in-
terviews were audiotaped, transcribed verbatim and translated into English for
thematic content analysis. RESULTS: Mixed beliefs were reported and a total of 4
themes were identified from the interview analysis: fear of termination of therapy
by the physicians, fear of interaction with the orthodox medicines, perceived dis-
interest by the physicians and perception that T&CM are simple and its discussion
to the physicians is irrelevant. Most of the patients agree that T&CM disclosure is
important to avoid any interaction with the chemotherapy or radiotherapy. On the
other hand, patients believe that T&CM discussion is not important due to the lack
of physicians’ knowledge & interest in discussing T&CM. A common perception
regarding the simplicity in nature of some of the non-invasive traditional modali-
ties such as prayers, spiritual & faith healing was reported as reasons of not dis-
closing T&CM use to the physicians. CONCLUSIONS: Understanding the underly-
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